AER-271
AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility; shows improved neurological outcome and reduced swelling in two models of CNS injury complicated by cerebral edema.Other Indication Phase 1 Clinical (In Vivo) :AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest.AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke.
Product Specifications
CAS Number
634913-39-6
Product Name Alternative
AER271
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 125 mg/mL (269.60 mM)
Smiles
O=P (O) (OC1=CC=C (Cl) C=C1C (NC2=CC (C (F) (F) F) =CC (C (F) (F) F) =C2) =O) O
Molecular Formula
C15H9ClF6NO5P
Molecular Weight
463.653
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-{[3,5-Bis (trifluoromethyl) phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SSBP3 Lentiviral Vector (Mouse) (CMV) (pLenti-GIII-CMV)
